Device Trial Radar · NCT07950956
A Prospective, Multicenter, Randomized, No-Treatment Controlled, Evaluator-Blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of a Medical Collagen Filler for Correcting Infraorbital Depression
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
171
Planned (sponsor's estimate)
Start
Dec 25, 2026
Primary completion
Jul 25, 2027
Study completion Jul 25, 2028
Sponsor
- Lead sponsor
- Fiman (Changchun) Pharmaceutical Biotechnology Company LimitedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Infraorbital hollowing, also known as tear trough deformity, refers to a sunken groove extending from the medial canthal region along the infraorbital rim downward and laterally. It is one of the key features of facial aging and remains one of the most challenging issues in periorbital rejuvenation \[1,2\]. This deformity is particularly common among Asian populations, with approximately 60%-70% of middle-aged individuals presenting with varying degrees of infraorbital hollowing \[2\]; its incidence increases significantly with age. The formation of infraorbital hollowing results from the combined effects of multiple factors, including anatomical changes, soft tissue atrophy, skin aging, and impaired lymphatic circulation \[2\]. Beyond compromising facial aesthetics, it creates negative impressions of fatigue, aging, and sternness, which can severely affect patients' psychological well-being and social lives \[3\]. In recent years, driven by growing demand for facial rejuvenation, infraorbital hollowing correction has become a popular non-surgical aesthetic procedure. However, due to the complex anatomy of the infraorbital region-characterized by thin skin, abundant vasculature, and fragile lymphatic drainage-traditional fillers are prone to issues such as migration, the Tyndall effect, and prolonged swelling, placing higher demands on both filling materials and injection techniques \[4\]. Collagen, as a natural biomaterial, offers distinct advantages for infraorbital hollowing correction owing to its excellent biocompatibility, low migration tendency, and light-scattering properties \[5\]. The mechanism of collagen injection for infraorbital hollowing correction is a complex, multi-stage, and multi-level process that achieves immediate physical volumization and tissue support. Injected collagen replenishes lost volume, forming a soft, cohesive fibrous structure that lifts the depressed area and restores a smooth transition between the lower eyelid and cheek, thereby reducing the hollowed appearance \[5,6\]. Meanwhile, due to its high adhesiveness, collagen binds loosened skin tissues together, repositions the disrupted fibrous scaffold network, and restores a youthful, firm contour \[6\]. After injection, the collagen gradually dehydrates and condenses, reorganizing into a fibrillar structure resembling native collagen in vivo, which further tightens tissues and enhances the supporting effect. The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd. was approved for marketing by the NMPA in 2016 (Registration Certificate No.: Guo Xie Zhu Zhun 20163131609). It is indicated for dermal filling of the face to correct moderate to severe nasolabial folds, and has demonstrated favorable efficacy and safety in clinical practice. The proposed new indication is infraorbital filling for the improvement and correction of infraorbital hollowing. The objective of this study is to evaluate the efficacy and safety of this medical collagen filler manufactured by Feifan (Changchun) Medical Biotechnology Co., Ltd. in correcting the severity of infraorbital hollowing. In accordance with the Measures for the Administration of Medical Device Registration and Filing, the Good Clinical Practice for Medical Device Clinical Trials (GCP), and the Guidelines for Medical Device Clinical Trial Design, and adhering to the ethical principles of the World Medical Association Declaration of Helsinki, this study strives to maximize benefits for research participants while minimizing potential harm.
Conditions
- Correcting Infraorbital Depression
Interventions
Medical collagen fillerDevice
The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scoresTime frame: 3 months after the last injection in the experimental group and at 3 months after randomization in the control group
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.